Fulminant hepatic failure associated with etodolac use.
Etodolac is a new pyranocarboxylic acid nonsteroidal anti-inflammatory agent with a unique chemical structure indicated for use in patients with painful musculoskeletal disorders and rheumatoid disease. Hepatotoxicity, in the form of reversible elevations in transaminases or bilirubin, occurs rarely. We present the first reported case of fulminant hepatic failure related to etodolac.
Mabee
C L
CL
Department of Gastroenterology, Ohio State University Medical Center, Columbus, USA.
Mabee
S W
SW
Baker
P B
PB
Kirkpatrick
R B
RB
Levine
E J
EJ
D000368:Aged; D017308:Etodolac / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006501:Hepatic Encephalopathy / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008111:Liver Function Tests
D017308:Etodolac